Navigation Links
SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA
Date:2/14/2008

IRVINE, Calif., Feb. 14 /PRNewswire/ -- SectorWatch.biz announces the availability of MarketStats on public equities that are in the news and driving markets today.

Investors can view all of SectorWatch.biz MarketStats free of charge by visiting: http://www.SectorWatch.biz -- Click on MarketStats

Today's MarketStats on Healthcare and Biotechnology companies include: CardioVascular Bio Therapeutics, Inc. (OTC Bulletin Board: CVBT), Boston Scientific Corp. (NYSE: BSX), Medtronic Inc. (NYSE: MDT), Cardium Therapeutics Inc. (Amex: CXM) and Genentech Inc. (NYSE: DNA).

To view a complete profile on CardioVascular Bio Therapeutics, Inc., visit our financial courier StockUpTicks.com (http://www.stockupticks.com).

Our MarketStats provide snapshots and analysis on public equities making news, driving industry sectors and affecting the markets. SectorWatch.biz is powered by Market Pathways, a leader in the representation of Small Cap equities for over twenty-five years. We are your discovery zone for under-followed stocks shaping the market.

Interested investors may subscribe for FREE to our StockUpTicks newsletter featuring a treasure trove of promising companies, daily market movers and free personal investment information -- visit http://stockupticks.com/register.html. D.R. Clark of Market Pathways is a member of the National Association of Securities Dealers, CRD # 4518163.

Contact us directly to have your company featured in StockUpTicks.com or SectorWatch.biz. For D.R. Clark's perspective on personal finance and the markets visit http://www.ClarkReport.com

Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz and StockUpTicks.com are properties of Market Pathways Financial Relations, Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report.

This report is neither a solicitation to buy nor an offer to sell securities but is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor, analyst or licensed broker dealer and this report is not investment advice. MP has been granted twenty thousand restricted shares of CVBT common stock by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.


'/>"/>
SOURCE SectorWatch.biz
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
2. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
3. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
4. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
5. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
6. CCPM Issues Statement on FDAs GIVE Initiative
7. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
8. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
9. HHS Issues First Department-Wide Report on Personalized Health Care
10. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
11. Pharmos Issues Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... ended December 31, 2015. --> ... a net loss of $29.3 million, or $0.34 loss per share, ... per share for the same period in 2014. For the year ... $88.9 million, or $1.05 loss per share, as compared to a ...
(Date:2/11/2016)... , Germany and ... QGEN ; Frankfurt Prime Standard: QIA) today ... Targeted RNA Panels for gene expression profiling, expanding QIAGEN,s ... (NGS). The panels enable researchers to select from over ... changes and discover interactions between genes, cellular phenotypes and ...
(Date:2/11/2016)... 2016  Spectra BioPharma Selling Solutions (Spectra) is ... biopharma companies the experience, expertise, operational delivery and ... sales teams. Created in concert with industry leading ... strategic and tactical needs of its clients by ... both personal and non-personal promotion. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... dedicated to delivering cutting-edge information focused on the development and manufacture of ... become a premier sponsor of the 2016 BioProcess International Awards – Recognizing ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):